

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Clover Biopharmaceuticals, Ltd.**

**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

**VOLUNTARY ANNOUNCEMENT  
CLOVER EXPANDS SALES AND DISTRIBUTION NETWORK  
FOR UPCOMING QUADRIVALENT SEASONAL  
INFLUENZA VACCINE LAUNCH IN CHINA**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business development of the Group.

The Company is pleased to announce that the Company has established a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co. Ltd. (科園信海(北京)醫療用品貿易有限公司) (“**Kyuan Trade**”), a leading pharmaceutical import and distribution company in China, as the Company prepares for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The Company expects to launch AdimFlu-S (QIS) in the second half of 2023.

This partnership with Kyuan Trade will support the Company’s execution of its commercial strategy for AdimFlu-S (QIS). Kyuan Trade’s extensive distribution network spans 31 provinces, municipalities and autonomous regions and more than 2,000 district and county centers for disease control. Kyuan Trade will complement the Company’s established and growing commercial capabilities to maximize access across China.

The market for the seasonal influenza vaccine in China has been growing by approximately 30% annually and is expected to continue growing in the post-pandemic era with increasing vaccine awareness and favorable government policies. Moreover, demand in China continues to shift from trivalent to quadrivalent seasonal influenza vaccines options, which accounted for the majority of doses (70%) in 2022. The Company anticipates that sales from AdimFlu-S (QIS) will be accretive to the Company’s earnings in 2023 and contribute meaningfully to growth in 2024 and beyond.

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, May 24, 2023

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*